NUPLAZID® (pimavanserin) 34 mg: The First and Only FDA-Approved Treatment for Parkinson's Disease Psychosis Addressing Serotonin Dysfunction in Parkinson's Disease Psychosis

Saturday, October 27
12:15 PM - 1:30 PM
Location: Tangerine WF3

Non-CME. Lunch will be served. Seating is limited.
Uncover the latest information, data, and research findings with disease-state or product-specific presentations. Ask questions of key experts and industry representatives and assess the value to your patient care. Seating is limited and available on a first-come, first-served basis. Innovation Theater presentations are not intended or eligible for CME/CE credit.

Speaker(s)
Gustavo Alva, MD, DFAPA
Medical Director, ATP Clinical Research, Costa Mesa, California; Assistant Professor, Department of Neuroscience, University of California Riverside

Dan Cotton
Port Charlotte, Florida

This presentation is provided by ACADIA Pharmaceuticals Inc.


Assets

NUPLAZID® (pimavanserin) 34 mg: The First and Only FDA-Approved Treatment for Parkinson's Disease Psychosis Addressing Serotonin Dysfunction in Parkinson's Disease Psychosis



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for NUPLAZID® (pimavanserin) 34 mg: The First and Only FDA-Approved Treatment for Parkinson's Disease Psychosis Addressing Serotonin Dysfunction in Parkinson's Disease Psychosis